Loading clinical trials...
Loading clinical trials...
Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome
Conditions
Interventions
daunorubicin hydrochloride
pegylated liposomal doxorubicin hydrochloride
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
November 1, 1996
Primary Completion Date
January 1, 2007
Last Updated
February 4, 2013
NCT04704661
NCT06066138
NCT05039801
NCT03715933
NCT07479732
NCT07156565
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions